GGHC
BBNX

Gilder Gagnon Howe & Co’s Beta Bionics BBNX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-162,649
Closed -$3.23M – 283
2025
Q3 		$3.23M Sell
162,649
-81,553
-33% -$1.43M 0.03% 176
2025
Q2 		$3.56M Buy
+244,202
New +$3.46M 0.04% 155

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Gilder Gagnon Howe & Co's BBNX Position: Q4 2025 in Review

Gilder Gagnon Howe & Co sold out of Beta Bionics (BBNX) in Q4 2025, closing a stake of 162,649 shares — an estimated $3.23M sold.

Gilder Gagnon Howe & Co first reported a position in BBNX in Q2 2025 and held it in 2 quarters. The position peaked at $3.56M in Q2 2025. 158 funds tracked by Wall St. Rank hold BBNX as of Q4 2025.

  • Gilder Gagnon Howe & Co reported no remaining Beta Bionics position as of Q4 2025 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 162,649 Beta Bionics shares in Q4 2025, an estimated $3.23M.
  • Gilder Gagnon Howe & Co first reported a position in Beta Bionics in Q2 2025 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Beta Bionics position peaked at $3.56M in Q2 2025.
  • 158 funds tracked by Wall St. Rank held Beta Bionics as of Q4 2025.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2025, filed 17 Feb 2026.